PT-141

PT-141 primarily acts as a melanocortin receptor agonist, with highest affinity for the melanocortin 4 receptor (MC4R) and melanocortin 1 receptor (MC1R). Research suggests the following mechanisms:

1. Central Nervous System: PT-141 activates MC4R in specific brain regions, particularly the hypothalamus and brainstem areas involved in sexual response. This activation is thought to influence neural pathways related to sexual desire and arousal.

2. Neurotransmitter Modulation: Studies indicate that PT-141 may increase dopamine release in the medial preoptic area, a region crucial for sexual motivation.

3. Peripheral Effects: PT-141’s interaction with MC1R on melanocytes has been studied for potential effects on skin pigmentation.

1. HSDD in Premenopausal Women:

• Multiple Phase III clinical trials have evaluated PT-141’s efficacy for HSDD.

• Studies typically measured changes in sexual desire and related distress using validated scales like the Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO).

• Research has examined various dosing regimens and administration methods.

2. Other Areas of Investigation:

• Male Sexual Function: Some studies have explored potential effects on erectile function, though this is not an FDA-approved use.

• Dermatology: Limited research has investigated PT-141’s influence on melanogenesis and potential applications in pigmentation disorders.

• Cardiovascular Effects: Studies have examined PT-141’s impact on blood pressure and heart rate, primarily for safety monitoring.